# Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00088959** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** celecoxib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00088959
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2009-01
- **Final completion:** 2010-11
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088959, "Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00088959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*